PMID- 36686490
OWN - NLM
STAT- MEDLINE
DCOM- 20230124
LR  - 20240226
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 13
DP  - 2022
TI  - The effect of low volume high-intensity interval training on metabolic and 
      cardiorespiratory outcomes in patients with type 2 diabetes mellitus: A 
      systematic review and meta-analysis.
PG  - 1098325
LID - 10.3389/fendo.2022.1098325 [doi]
LID - 1098325
AB  - AIMS: The present systematic review and meta-analysis of randomized controlled 
      trials (RCTs) was conducted to investigate the effect of low volume 
      high-intensity interval training (LVHIIT) on the metabolic and cardiorespiratory 
      outcomes in patients with type 2 diabetes mellitus (T2DM). METHODS: Relevant 
      articles were sourced from PubMed, EBSCO, Web of Science, Embase, and the 
      Cochrane Library from inception to October 2022. The study search strategy and 
      all other processes were implemented in accordance with the PRISMA statement. 
      RESULTS: Five randomized controlled trials that satisfied the inclusion criteria 
      were included in this meta-analysis. The LVHIIT group had significantly lower 
      fasting blood glucose levels (RR= -1.21; 95% CI= -2.02- -0.40, p = 0.0032) and 
      HbA1c levels (RR= -0.65; 95% CI= -1.06- -0.23, p = 0.002) and higher levels of 
      insulin resistance indicator HOMA-IR (RR= -1.34; 95% CI = -2.59- -0.10, p = 0.03) 
      than the control group. Moreover, our results show that LVHIIT can reduce body 
      mass (RR = -0.94, 95% CI = -1.37- -0.51, p<0.0001) and body mass index (RR = 
      -0.31, 95% CI = -0.47- -0.16, p<0.0001). LVHIIT had a better therapeutic effect 
      on blood lipid metabolism, such as total cholesterol, high-density lipoprotein, 
      low-density lipoprotein and triglycerides. However, the change in fasting insulin 
      levels was not statistically significant (RR= -1.43; 95% CI = -3.46- 0.60, p 
      =0.17). Furthermore, LVHIIT reduced the systolic blood pressure (RR =-4.01, 95% 
      CI = -4.82 - -3.21, p<0.0001) and improved peak oxygen uptake (VO(2peak)) 
      compared to the control group (RR= 5.45; 95% CI = 1.38 - 9.52, p =0.009). 
      CONCLUSION: After a certain period of LVHIIT, glycaemic control, insulin 
      resistance, body weight, lipid profile and cardiorespiratory outcomes were 
      significantly improved in T2DM patients.
CI  - Copyright (c) 2023 Peng, Ou, Wang, Wang and Zheng.
FAU - Peng, Yang
AU  - Peng Y
AD  - West China Hospital/West China School of Medicine, Sichuan University, Chengdu, 
      China.
FAU - Ou, Yiran
AU  - Ou Y
AD  - Department of Endocrinology and Metabolism, Center for Diabetes and Metabolism 
      Research, West China Hospital, Sichuan University, Chengdu, China.
FAU - Wang, Ke
AU  - Wang K
AD  - Department of Vascular Surgery, University Hospital of Chengdu University of 
      Traditional Chinese Medicine, Chengdu, China.
FAU - Wang, Zhenghao
AU  - Wang Z
AD  - Department of Endocrinology and Metabolism, Center for Diabetes and Metabolism 
      Research, West China Hospital, Sichuan University, Chengdu, China.
AD  - The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska 
      Institutet, Stockholm, Sweden.
FAU - Zheng, Xiaofeng
AU  - Zheng X
AD  - Department of Endocrinology and Metabolism, Center for Diabetes and Metabolism 
      Research, West China Hospital, Sichuan University, Chengdu, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20230104
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
SB  - IM
MH  - Humans
MH  - *Insulin Resistance
MH  - *High-Intensity Interval Training
MH  - *Diabetes Mellitus, Type 2/complications/therapy
MH  - Body Weight
MH  - Body Mass Index
PMC - PMC9845913
OTO - NOTNLM
OT  - cardiorespiratory outcomes
OT  - low volume high-intensity interval training
OT  - meta-analysis
OT  - metabolism outcome
OT  - type 2 diabetes mellitus
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/01/24 06:00
MHDA- 2023/01/25 06:00
PMCR- 2022/01/01
CRDT- 2023/01/23 04:51
PHST- 2022/11/14 00:00 [received]
PHST- 2022/12/13 00:00 [accepted]
PHST- 2023/01/23 04:51 [entrez]
PHST- 2023/01/24 06:00 [pubmed]
PHST- 2023/01/25 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2022.1098325 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2023 Jan 4;13:1098325. doi: 
      10.3389/fendo.2022.1098325. eCollection 2022.